Media coverage about Merrimack Pharmaceuticals (NASDAQ:MACK) has been trending somewhat positive recently, Accern reports. The research group identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Merrimack Pharmaceuticals earned a coverage optimism score of 0.02 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 48.0154908756654 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Several equities research analysts recently commented on the company. Robert W. Baird reissued a “hold” rating and set a $12.00 target price on shares of Merrimack Pharmaceuticals in a report on Thursday, March 15th. Zacks Investment Research raised Merrimack Pharmaceuticals from a “hold” rating to a “buy” rating and set a $9.75 target price on the stock in a report on Wednesday, May 2nd.
Merrimack Pharmaceuticals stock traded up $0.02 during mid-day trading on Thursday, hitting $9.05. The company’s stock had a trading volume of 34,687 shares, compared to its average volume of 131,789. The firm has a market cap of $120.89 million, a price-to-earnings ratio of -1.60 and a beta of 1.80. Merrimack Pharmaceuticals has a twelve month low of $7.36 and a twelve month high of $15.40.
Merrimack Pharmaceuticals (NASDAQ:MACK) last posted its quarterly earnings results on Monday, March 12th. The biopharmaceutical company reported ($0.89) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.27) by $0.38. analysts predict that Merrimack Pharmaceuticals will post -4.66 EPS for the current fiscal year.
About Merrimack Pharmaceuticals
Merrimack Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on biomarker-defined cancers in the United States. The company's clinical programs include MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive non-small cell lung cancer; and MM-141, a human tetravalent bispecific antibody that is in Phase II clinical trial for treating patients with metastatic pancreatic cancer with high serum levels of free insulin-like growth factor 1.
Receive News & Ratings for Merrimack Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.